Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GNFTNASDAQ:OTLKNASDAQ:PROKNASDAQ:TNXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNFTGenfit$4.34-3.8%$3.82$2.55▼$6.42$216.83M0.9213,561 shs2,084 shsOTLKOutlook Therapeutics$1.77-3.8%$1.48$0.87▼$9.25$59.42M0.39778,212 shs1.77 million shsPROKProKidney$0.75+3.2%$0.77$0.46▼$3.94$218.32M1.5672,593 shs441,828 shsTNXPTonix Pharmaceuticals$38.06-4.3%$21.50$6.76▼$549.12$278.79M1.63894,372 shs616,623 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNFTGenfit0.00%+3.55%+2.34%+28.82%-15.44%OTLKOutlook Therapeutics0.00%+15.63%+19.35%+30.28%-73.83%PROKProKidney0.00%-0.31%-10.24%-35.31%-79.64%TNXPTonix Pharmaceuticals0.00%+37.57%+99.00%+439.30%-92.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGNFTGenfit2.3957 of 5 stars3.55.00.00.02.90.00.0OTLKOutlook Therapeutics1.8354 of 5 stars3.43.00.00.01.90.00.6PROKProKidney2.255 of 5 stars3.30.00.00.02.74.20.6TNXPTonix Pharmaceuticals3.7188 of 5 stars3.54.00.00.03.23.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGNFTGenfit 3.00Buy$13.00199.75% UpsideOTLKOutlook Therapeutics 2.80Moderate Buy$10.20476.27% UpsidePROKProKidney 2.50Moderate Buy$5.00570.33% UpsideTNXPTonix Pharmaceuticals 3.00Buy$585.001,437.05% UpsideCurrent Analyst Ratings BreakdownLatest OTLK, TNXP, GNFT, and PROK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025OTLKOutlook TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/20/2025TNXPTonix PharmaceuticalsNoble FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$70.00 ➝ $70.00(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGNFTGenfit$67.00M3.24N/AN/A$1.48 per share2.93OTLKOutlook TherapeuticsN/AN/AN/AN/A($1.57) per shareN/APROKProKidney$306K713.48N/AN/A($4.84) per share-0.15TNXPTonix Pharmaceuticals$10.04M27.77N/AN/A$5,751.80 per share0.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGNFTGenfit-$31.27MN/A0.00N/AN/AN/AN/AN/A7/24/2025 (Estimated)OTLKOutlook Therapeutics-$75.37M-$0.91N/AN/AN/AN/AN/A-225.12%8/13/2025 (Estimated)PROKProKidney-$35.47M-$0.60N/AN/AN/AN/AN/A-10.24%8/8/2025 (Estimated)TNXPTonix Pharmaceuticals-$116.66M-$1,963.61N/AN/AN/A-1,197.86%-163.95%-118.88%8/15/2025 (Estimated)Latest OTLK, TNXP, GNFT, and PROK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q2 2025OTLKOutlook Therapeutics-$0.55-$0.40+$0.15-$1.50$0.70 millionN/A5/12/2025Q1 2025PROKProKidney-$0.16-$0.13+$0.03-$0.13N/A$0.23 million5/12/2025Q1 2025TNXPTonix Pharmaceuticals-$3.23-$2.84+$0.39-$2.84$2.55 million$2.43 million3/18/2025Q4 2024TNXPTonix Pharmaceuticals-$6.23-$9.77-$3.54-$9.77$3.20 million$2.58 million3/17/2025Q4 2024PROKProKidney-$0.14-$0.17-$0.03-$0.17N/A$0.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGNFTGenfitN/AN/AN/AN/AN/AOTLKOutlook TherapeuticsN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGNFTGenfit0.613.743.74OTLKOutlook TherapeuticsN/A0.320.64PROKProKidneyN/A17.0817.09TNXPTonix Pharmaceuticals0.073.332.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGNFTGenfit2.24%OTLKOutlook Therapeutics11.20%PROKProKidney51.59%TNXPTonix Pharmaceuticals82.26%Insider OwnershipCompanyInsider OwnershipGNFTGenfit4.20%OTLKOutlook Therapeutics4.80%PROKProKidney41.49%TNXPTonix Pharmaceuticals0.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGNFTGenfit12050.00 million47.90 millionNot OptionableOTLKOutlook Therapeutics2033.57 million30.48 millionOptionablePROKProKidney3292.70 million170.65 millionOptionableTNXPTonix Pharmaceuticals507.33 million1.87 millionNot OptionableOTLK, TNXP, GNFT, and PROK HeadlinesRecent News About These CompaniesTonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 4.1% - What's Next?June 2 at 2:22 PM | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Downgraded by Wall Street Zen to "Sell"June 1 at 2:07 AM | americanbankingnews.comZacks Small Cap Issues Optimistic Forecast for TNXP EarningsJune 1 at 1:21 AM | americanbankingnews.comTonix Pharmaceuticals (NASDAQ:TNXP) Cut to Sell at Wall Street ZenMay 31 at 12:31 AM | marketbeat.comTonix Pharmaceuticals: August PDUFA Date For Fibromyalgia Med A Risky BetMay 30 at 4:21 PM | seekingalpha.comTonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 3.6% - Here's WhyMay 30 at 1:38 PM | marketbeat.comZacks Small Cap Brokers Boost Earnings Estimates for TNXPMay 30 at 5:52 AM | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 9.1% - Should You Buy?May 29, 2025 | marketbeat.comJane Street Group LLC Purchases 1,635,119 Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)May 29, 2025 | marketbeat.comWhat's Going On With Tonix Pharmaceuticals Stock?May 28, 2025 | benzinga.comTonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 6% - Time to Sell?May 28, 2025 | marketbeat.comTNXP: Preparations Continue for Potential Commercial Launch of TNX-102 SL in Fibromyalgia…May 28, 2025 | finance.yahoo.comTonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 9% - Here's WhyMay 27, 2025 | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Trading 2.8% Higher - Still a Buy?May 25, 2025 | marketbeat.comPoint72 Asset Management L.P. Makes New $526,000 Investment in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)May 25, 2025 | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Upgraded at Wall Street ZenMay 24, 2025 | marketbeat.comTonix Pharmaceuticals CEO Seth Lederman Participates in A.G.P. Annual Healthcare Company ShowcaseMay 22, 2025 | quiverquant.comTonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company ShowcaseMay 22, 2025 | globenewswire.comTonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress ReactionMay 21, 2025 | globenewswire.comTonix Pharmaceuticals (NASDAQ:TNXP) Shares Pass Above 200-Day Moving Average - Here's WhyMay 17, 2025 | marketbeat.comTonix Pharmaceuticals (TNXP) Stock Surges Following Insider Buying And Q1 ResultsMay 16, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOTLK, TNXP, GNFT, and PROK Company DescriptionsGenfit NASDAQ:GNFT$4.28 -0.23 (-5.10%) As of 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Outlook Therapeutics NASDAQ:OTLK$1.77 -0.07 (-3.80%) Closing price 04:00 PM EasternExtended Trading$1.76 -0.01 (-0.28%) As of 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.ProKidney NASDAQ:PROK$0.75 +0.02 (+3.20%) Closing price 04:00 PM EasternExtended Trading$0.74 0.00 (-0.39%) As of 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.Tonix Pharmaceuticals NASDAQ:TNXP$38.06 -1.72 (-4.32%) Closing price 04:00 PM EasternExtended Trading$38.12 +0.06 (+0.17%) As of 05:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Will Hit $360 Soon: Here’s the How and Why Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell 5 Reasons Costco Stock Will Hit New Highs This Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
